Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

41. Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy

Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy HealthPACT Health Policy Advisory Committee on Technology Australia and New Zealand Technology Brief 90Y Zevalin for the treatment of non-Hodgkin’s lymphoma (v1.0) August 2011 © State of Queensland (Queensland Health) 2011 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 2.5 Australia licence. In essence, you are free to copy and communicate the work in its current form

COAG Health Council - Horizon Scanning Technology Briefs2018

42. Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial

Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial 29273691 2017 12 23 1468-330X 2017 Dec 22 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised (...) prospective clinical trial. jnnp-2017-316311 10.1136/jnnp-2017-316311 To compare the effects of different surgical approaches for selective amygdalohippocampectomy in patients with pharmacoresistant mesial temporal lobe epilepsy with regard to the neuropsychological outcome and to replicate an earlier study employing a matched-pair design. 47 patients were randomised to subtemporal versus transsylvian approaches. Memory, language, attentional and executive functions were assessed before and 1 year after

EvidenceUpdates2018

43. Management of epilepsy in adults with intellectual disability

Management of epilepsy in adults with intellectual disability CR203 Browser does not support script. Browser does not support script. Improving the lives of people with mental illness Browser does not support script. CR203. Management of epilepsy in adults with intellectual disability Price: £0.00 Approved: Apr 2017 Published: May 2017 Status: current Number of pages: 49 Review by: 2022 This report is available online-only. There are no print copies to buy. This long-awaited report offers (...) an important step towards clarifying the role of the psychiatrist in ID in the management of epilepsy. The proposed tiered system of professional competency gives psychiatrists the option to identify their role in care provision and ensures a framework for training. It provides a structure from which a competency evaluation can be developed. The vision should be for all psychiatrists working with people with ID to have training and certification to one of the three levels of competency (Bronze, Silver

Royal College of Psychiatrists2018

44. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability

Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability CR206 Browser does not support script. Browser does not support script. Improving the lives of people with mental illness Browser does not support script. CR206. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability Price: £0.00 Approved: Aug 2017 Published: Oct 2017 Status: current Number of pages: 60 Review by: 2022 This report addresses the extremely important area (...) of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social isolation. An individual who experiences both these problems faces huge challenges. Contents Working group Foreword Scope of this report Executive summary Guiding principles Background Objectives and methodology Summary of evidence Evidence of the use of specific AEDs in people with ID Choosing the most appropriate AED Prescribing guidance

Royal College of Psychiatrists2018

45. Diagnosis and management of epilepsy in adults

Diagnosis and management of epilepsy in adults SIGN 143 • Diagnosis and management of epilepsy in adults A national clinical guideline Evidence May 2015 · Revised 2018KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias (...) in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Diagnosis and management of epilepsy in adults A national clinical guideline Revised 2018Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published

SIGN2018

46. Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome)

Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) Final Appraisal Recommendation Advice No: 2617 – November 2017 Stiripentol (Diacomit ® ) 250 mg and 500 mg hard capsules; 250 mg and 500 mg powder for oral suspension in sachet Resubmission by Biocodex Additional note(s): • AWMSG considered that stiripentol (Diacomit (...) (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Stiripentol (Diacomit ® ) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled

All Wales Medicines Strategy Group2017

47. Psychological treatments for people with epilepsy.

Psychological treatments for people with epilepsy. BACKGROUND: Given the significant impact epilepsy can have on the health-related quality of life (HRQoL) of individuals with epilepsy and their families, there is great clinical interest in evidence-based psychological treatments, aimed at enhancing psychological well-being in people with epilepsy. A review of the current evidence was needed to assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes, in order (...) to inform future therapeutic recommendations and research designs. OBJECTIVES: To assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes. SEARCH METHODS: We searched the following databases on 20 September 2016, without language restrictions: Cochrane Epilepsy Group Specialized Register, CENTRAL, MEDLINE PsycINFO, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP). We screened the references from included studies and relevant reviews

Cochrane2017

48. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery.

Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. BACKGROUND: Detailed neuropathological information on the structural brain lesions underlying seizures is valuable for understanding drug-resistant focal epilepsy. METHODS: We report the diagnoses made on the basis of resected brain specimens from 9523 patients who underwent epilepsy surgery for drug-resistant seizures in 36 centers from 12 European countries over 25 years. Histopathological diagnoses were determined (...) through examination of the specimens in local hospitals (41%) or at the German Neuropathology Reference Center for Epilepsy Surgery (59%). RESULTS: The onset of seizures occurred before 18 years of age in 75.9% of patients overall, and 72.5% of the patients underwent surgery as adults. The mean duration of epilepsy before surgical resection was 20.1 years among adults and 5.3 years among children. The temporal lobe was involved in 71.9% of operations. There were 36 histopathological diagnoses in seven

NEJM2017

49. Surgery for Drug-Resistant Epilepsy in Children.

Surgery for Drug-Resistant Epilepsy in Children. BACKGROUND: Neurosurgical treatment may improve seizures in children and adolescents with drug-resistant epilepsy, but additional data are needed from randomized trials. METHODS: In this single-center trial, we randomly assigned 116 patients who were 18 years of age or younger with drug-resistant epilepsy to undergo brain surgery appropriate to the underlying cause of epilepsy along with appropriate medical therapy (surgery group, 57 patients (...) ; 95% CI, 16.4 to 27.6; P<0.001), and on the Vineland Social Maturity Scale (difference, 4.7; 95% CI, 0.4 to 9.1; P=0.03), but not on the Binet-Kamat intelligence quotient (difference, 2.5; 95% CI, -0.1 to 5.1; P=0.06). Serious adverse events occurred in 19 patients (33%) in the surgery group, including hemiparesis in 15 (26%). CONCLUSIONS: In this single-center trial, children and adolescents with drug-resistant epilepsy who had undergone epilepsy surgery had a significantly higher rate

NEJM2017

50. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.

Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. BACKGROUND: This is an updated version of the Cochrane Review published in the Cochrane Library 2011, Issue 12.The majority of people with epilepsy have a good prognosis, but up to 30% of people continue to have seizures despite several regimens of antiepileptic drugs. In this review, we summarized the current evidence regarding eslicarbazepine acetate (ESL) when used as an add-on treatment for drug-resistant partial epilepsy (...) . OBJECTIVES: To evaluate the efficacy and tolerability of ESL when used as an add-on treatment for people with drug-resistant partial epilepsy. SEARCH METHODS: The searches for the original review were run in November 2011. Subsequently, we searched the Cochrane Epilepsy Group Specialized Register (6 December 2016), the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 11) and MEDLINE (1946 to 6 December 2016). There were no language restrictions. We reviewed the reference lists

Cochrane2017

51. The role of high-frequency oscillations in epilepsy surgery planning.

The role of high-frequency oscillations in epilepsy surgery planning. BACKGROUND: Epilepsy is a serious brain disorder characterized by recurrent unprovoked seizures. Approximately two-thirds of seizures can be controlled with antiepileptic medications (Kwan 2000). For some of the others, surgery can completely eliminate or significantly reduce the occurrence of disabling seizures. Localization of epileptogenic areas for resective surgery is far from perfect, and new tools are being (...) investigated to more accurately localize the epileptogenic zone (the zone of the brain where the seizures begin) and improve the likelihood of freedom from postsurgical seizures. Recordings of pathological high-frequency oscillations (HFOs) may be one such tool. OBJECTIVES: To assess the ability of HFOs to improve the outcomes of epilepsy surgery by helping to identify more accurately the epileptogenic areas of the brain. SEARCH METHODS: For the latest update, we searched the Cochrane Epilepsy Group

Cochrane2017

52. Yoga for epilepsy.

Yoga for epilepsy. BACKGROUND: This is an updated version of the original Cochrane Review published in the Cochrane Library, Issue 5, 2015.Yoga may induce relaxation and stress reduction, and influence the electroencephalogram and the autonomic nervous system, thereby controlling seizures. Yoga would be an attractive therapeutic option for epilepsy if proved effective. OBJECTIVES: To assess whether people with epilepsy treated with yoga:(a) have a greater probability of becoming seizure free;(b (...) ) have a significant reduction in the frequency or duration of seizures, or both; and(c) have a better quality of life. SEARCH METHODS: For this update, we searched the Cochrane Epilepsy Group Specialized Register (3 January 2017), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 12) in the Cochrane Library (searched 3 January 2017), MEDLINE (Ovid, 1946 to 3 January 2017), SCOPUS (1823 to 3 January 2017), ClinicalTrials.gov (searched 3 January 2017), the World Health

Cochrane2017

53. Lacosamide - Epilepsy

Lacosamide - Epilepsy 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 20 July 2017 EMA/518597/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lacosamide Accord International non-proprietary name (...) -onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC) The application submitted is composed of administrative information, complete quality data and literature from the reference medicinal product Vimpat instead of non-clinical and clinical unless justified otherwise. The chosen reference product is: Medicinal product which

European Medicines Agency - EPARs2017

54. Stiripentol (Diacomit) - adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet?s syndrome)

Stiripentol (Diacomit) - adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet?s syndrome)

Scottish Medicines Consortium2017

55. Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017

Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017 28979739 2018 11 13 2008-5842 9 8 2017 Aug Electronic physician Electron Physician Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017. 5036-5042 10.19082/5036 Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent non-communicable diseases. There are no recently published data on the prevalence of epilepsy in school children (...) in Northern Saudi Arabia. This study was conducted to determine the prevalence of epilepsy and to show some of its risk factors in school children and adolescents (6-18 years) in Turaif city, Northern Saudi Arabia. This, population-based, cross-sectional study was conducted in Turaif city, over a 6-month period, from July 2016 to January 2017. It included pupils aged 6 to18 years in all primary, preparatory and secondary schools in Turaif city. Multi-stage sampling was employed. A designated structured

Electronic physician2017 Full Text: Link to full Text with Trip Pro

56. Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy

Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy 28752020 2018 11 13 2193-6358 78 3 2017 Jul Journal of neurological surgery reports J Neurol Surg Rep Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy. e101-e105 10.1055/s-0037-1604281 Introduction Epidermoid tumors represent approximately 0.3 to 1.8% of all intracranial brain tumors. Only 1.5% of all intracranial epidermoid cysts (ECs) invade the brain and secondary epilepsy is extremely rare. Since August 2014, a 59 (...) of involvement of hippocampus and amygdala. Conclusion Epilepsy secondary to ECs is a rare association. Lesionectomy can be an option with good results without increasing the morbidity. Trindade Vinicius Gomes VG Division of Neurosurgery, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil. Gomes Marcos de Queiroz Teles MQT Division of Neurosurgery, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil. Santo Marcelo Prudente do Espirito MPDE Division of Neurosurgery

Journal of neurological surgery reports2017 Full Text: Link to full Text with Trip Pro

57. Felbamate as an add-on therapy for refractory partial epilepsy.

Felbamate as an add-on therapy for refractory partial epilepsy. BACKGROUND: This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 7, 2014) on 'Felbamate as an add-on therapy for refractory epilepsy'. Epilepsy is a chronic and disabling neurologic disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available drugs. Felbamate is one of the second-generation (...) antiepileptic drugs and we have assessed its effects as an add-on therapy to standard drugs in this review. OBJECTIVES: To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with refractory partial-onset epilepsy. SEARCH METHODS: For the latest update we searched the Cochrane Epilepsy Specialized Register, CENTRAL, MEDLINE, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, up to 20 October 2016. There were no language

Cochrane2017

58. Intravenous immunoglobulins for epilepsy.

Intravenous immunoglobulins for epilepsy. BACKGROUND: Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may represent a valuable approach and its efficacy has important (...) implications for epilepsy management. This is an updated version of the original Cochrane review published in Issue 1, 2011. OBJECTIVES: To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects when used as monotherapy or as add-on treatment for people with epilepsy. SEARCH METHODS: For the latest update, we searched the Cochrane Epilepsy Group Specialized Register (2 February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via

Cochrane2017

59. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy]

[Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de

Health Technology Assessment (HTA) Database.2017

60. [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)]

[Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] Mengarelli C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mengarelli C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L. [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 522. 2017 Authors' conclusions

Health Technology Assessment (HTA) Database.2017